Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Brunette, M. F. Articles by Drake, R. E. Search for Related Content PubMed Citation Articles by Brunette, M. F. Articles by Drake, R. E. Chronically Mentally Ill Patients Dual Diagnosis Patients Anxiolytics

Benzodiazepine Use and Abuse Among Patients With Severe Mental Illness and Co-occurring Substance Use Disorders

OBJECTIVES: Because use of benzodiazepines may exacerbate existing substance use disorders or become abused substances, prescription of benzodiazepines for patients with severe mental illness (schizophrenia or bipolar disorder) and co-occurring substance use disorders (abuse or dependence) is controversial. The authors examined benzodiazepine use and associated psychiatric, substance abuse, and institutional outcomes in a six-year longitudinal study of patients with co-occurring disorders. METHODS: At baseline and yearly follow-up for six years, 203 patients with co-occurring severe mental illness and substance use disorder were prospectively assessed for medication use, substance use, psychiatric symptoms, use of hospitalization, and quality of life. RESULTS: Almost one-half of the patients (43 percent) reported taking prescribed benzodiazepines at the time of at least one assessment. Patients taking prescribed benzodiazepines were more likely to have high scores on measures of overall symptoms and affective symptoms (anxiety and depression) and low ratings for general quality of life throughout the study. Benzodiazepine use was unrelated to remission of substance use disorder or hospitalization, but a greater proportion of patients who were prescribed benzodiazepines developed benzodiazepine abuse, compared with those who were not prescribed benzodiazepines (15 percent compared with 6 percent). CONCLUSIONS: Prescription benzodiazepine use was common among patients with co-occurring severe mental illness and a substance use disorder and was not associated with any of the measured outcomes other than increasing the likelihood of benzodiazepine abuse. Physicians should consider other treatments for anxiety in this population.

This article has been cited by other articles:

				K. R. Merikangas, R. Herrell, J. Swendsen, W. Rossler, V. Ajdacic-Gross, and J. Angst Specificity of Bipolar Spectrum Conditions in the Comorbidity of Mood and Substance Use Disorders: Results From the Zurich Cohort Study Arch Gen Psychiatry, January 1, 2008; 65(1): 47 - 52. [Abstract] [Full Text] [PDF]

				S.L. de Haas, S.J. de Visser, J.P. van der Post, M. de Smet, R.C. Schoemaker, B. Rijnbeek, A.F. Cohen, J.M. Vega, N.G.B. Agrawal, T.V. Goel, et al. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA {alpha}2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers J Psychopharmacol, June 1, 2007; 21(4): 374 - 383. [Abstract] [PDF]

				K. R. R. Krishnan Psychiatric and Medical Comorbidities of Bipolar Disorder Psychosom Med, January 1, 2005; 67(1): 1 - 8. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us